| Literature DB >> 29304140 |
Mariana Maia Freire de Oliveira1, Maria Salete Costa Gurgel1, Bárbara Juarez Amorim2, Celso Dario Ramos2, Sophie Derchain1, Natachie Furlan-Santos1, César Cabello Dos Santos1, Luís Otávio Sarian1.
Abstract
PURPOSE: evaluate whether manual lymphatic drainage (MLD) or active exercise (AE) is associated with shoulder range of motion (ROM), wound complication and changes in the lymphatic parameters after breast cancer (BC) surgery and whether these parameters have an association with lymphedema formation in the long run.Entities:
Mesh:
Year: 2018 PMID: 29304140 PMCID: PMC5755747 DOI: 10.1371/journal.pone.0189176
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flowchart of study sample.
Visual classification of upper limb lymphoscintigraphy.
| Score | Velocity visualization of axillary lymph nodes (VVAL) | Score | Degree uptake in axillary lymph nodes (DUALN) |
|---|---|---|---|
| 1 | Not visualized | 1 | Absent |
| 2 | After two hours | 2 | Mild |
| 3 | After one hour | 3 | Moderate |
| 4 | At 10 minutes | 4 | Intense |
Main clinical features of the women in the AE and MLD groups.
| AE | MLD | p-value | |||
|---|---|---|---|---|---|
| n | % | N | % | ||
| 0.84 | |||||
| <55 years | 22 | 41.5 | 24 | 45.3 | |
| ≥55 years | 31 | 58.5 | 29 | 54.7 | |
| 0.53 | |||||
| <25 Kg/m2 | 15 | 28.3 | 19 | 35.8 | |
| ≥25 Kg/m2 | 38 | 71.7 | 34 | 64.2 | |
| 0.0786 | |||||
| MRM Patey | 29 | 54.7 | 19 | 35.8 | |
| MRM Madden | 24 | 45.3 | 33 | 62.3 | |
| RM Halsted | 0 | 0.0 | 1 | 1.9 | |
| 0.8455 | |||||
| Right | 29 | 54.7 | 28 | 52.8 | |
| Left | 24 | 45.3 | 25 | 47.2 | |
| 1.0000 | |||||
| Right | 49 | 92.2 | 50 | 94.3 | |
| Left | 4 | 7.5 | 3 | 5.7 | |
| 0.0705 | |||||
| I | 1 | 2.0 | 0 | 0.0 | |
| II | 17 | 34.0 | 9 | 18.0 | |
| III/IV | 32 | 64.0 | 43 | 82.0 | |
| 0.0915 | |||||
| I | 2 | 3.8 | 1 | 1.9 | |
| II | 20 | 37.7 | 11 | 20.8 | |
| III/IV | 31 | 58.5 | 41 | 77.4 | |
| 0.2703 | |||||
| 1 | 2 | 3.8 | 0 | 0.0 | |
| 2 or 3 | 51 | 96.3 | 53 | 100.0 | |
| 0.0187 | |||||
| Yes | 24 | 45.3 | 36 | 67.9 | |
| No | 29 | 54.7 | 17 | 32.1 | |
| 0.0690 | |||||
| Yes | 8 | 36.4 | 18 | 62.1 | |
| No | 14 | 63.6 | 11 | 37.9 | |
| 0.2901 | |||||
| Yes | 16 | 72.7 | 26 | 86.7 | |
| No | 6 | 27.3 | 4 | 13.3 | |
| 0.1783 | |||||
| Plastron | 1 | 6.3 | 6 | 23.1 | |
| Plastron+SCF | 14 | 87.5 | 18 | 69.2 | |
| Plastron+SCF+Axilla | 0 | 0.0 | 2 | 7.7 | |
| Plastron+SCF+Cervical region | 1 | 6.3 | 0 | 0.0 | |
| 0.790 | |||||
| Yes | 14 | 63.6 | 18 | 60.0 | |
| No | 8 | 36.4 | 12 | 40.0 | |
| 1.000 | |||||
| Yes | 3 | 13.6 | 5 | 16.7 | |
| No | 19 | 86.4 | 25 | 83.3 | |
| 0.449 | |||||
| Fracture | 1 | 1.9 | 5 | 9.6 | |
| Luxation | 1 | 1.9 | 0 | 0.0 | |
| Bursitis | 2 | 3.8 | 2 | 3.8 | |
| Tendinitis | 5 | 9.6 | 5 | 9.6 | |
| Unknown pain | 6 | 11.5 | 9 | 17.3 | |
| Absent | 37 | 71.2 | 31 | 59.6 | |
| 0.3757 | |||||
| Yes | 9 | 36.0 | 16 | 64.0 | |
| No | 13 | 48.1 | 14 | 51.9 | |
| 1.0000 | |||||
| Yes | 2 | 40.0 | 3 | 60.0 | |
| No | 20 | 42.5 | 27 | 57.5 | |
| 0.4575 | |||||
| Yes | 8 | 36.4 | 14 | 63.6 | |
| No | 14 | 46.7 | 16 | 53.3 | |
| 0.3481 | |||||
| Follows daily | 15 | 68.2 | 17 | 56.7 | |
| Follows partly | 5 | 22.7 | 12 | 40.0 | |
| No follows | 2 | 9.1 | 1 | 3.3 | |
| 0.2201 | |||||
| Yes | 16 | 40.0 | 24 | 60.0 | |
| No | 33 | 52.4 | 30 | 47.6 | |
| 0.1114 | |||||
| Yes | 13 | 37.1 | 22 | 62.9 | |
| No | 36 | 53.7 | 31 | 46.3 | |
| 0.8280 | |||||
| Yes | 6 | 50.0 | 6 | 50.0 | |
| No | 42 | 46.7 | 48 | 53.3 | |
| 0.2723 | |||||
| Yes | 15 | 55.6 | 12 | 44.4 | |
| No | 32 | 43.2 | 42 | 56.8 | |
MRM = modified radical mastectomy; RM = radical mastectomy; SCF = supraclavicular fossa; UL = upper limbs/ Chi-Square test;
(*) Fisher’s Exact test
Fig 2Mean shoulder flexion (2A) and abduction (2B) at the preoperative of surgery, two and thirty months later, according to group.
Lymphocintigraphy parameters DUALN, VVAL, DBFL, CC and RAL as related to cumulative incidence of lymphedema by the end of follow-up.
| Lymphedema | Lymphedema | Lymphedema | Lymphedema | Lymphedema | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes (n = 15) | No (n = 48) | Yes (n = 15) | No (n = 48) | Yes (n = 15) | No (n = 48) | Yes (n = 15) | No (n = 48) | Yes (n = 15) | No (n = 48) | ||||||
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | ||||||
| DUALN | VVAL | DBFL | CC | RAL | |||||||||||
| Intense | 4(15) | 22(85) | At 10 minute | 4 (15) | 23 (85) | Present | 0 | 0 | Present | 3(21) | 11(79) | Present | 5(21) | 19(79) | |
| Moderate | 2(13) | 13(87) | After one hours | 5(21) | 19 (79) | Absent | 14(24) | 45(76) | Absent | 10(23) | 34(77) | Absent | 10(26) | 28(74) | |
| Mild | 4(25) | 12(75) | After two hour | 1 (17) | 5 (83) | P | <0.001 | P | 1 | p | 0.842 | ||||
| Absent | 5(100) | 0(0) | Not visualized | 5 (100) | 0(0) | ||||||||||
| p(Trend) | 0.003 | p(Trend) | 0.001 | ||||||||||||
| Intense | 2(12) | 15(88) | At 10 minute | 3(19) | 13(81) | Present | 1(33) | 2(67) | Present | 1(8) | 12(92) | Present | 10(23) | 33(77) | |
| Moderate | 1(8) | 12(92) | After one hours | 3(12.5) | 21(87.5) | Absent | 12(22) | 43(78) | Absent | 14(31) | 31(69) | Absent | 5(26) | 14(73) | |
| Mild | 9(39) | 14(61) | After two hour | 6(46) | 7(54) | P | 1 | P | 0.1806 | p | 1 | ||||
| Absent | 2(33) | 4(67) | Not visualized | 2(33) | 4(67) | ||||||||||
| p(Trend) | <0.001 | p(Trend) | 0.1115 | ||||||||||||
| Intense | 0 (0) | 2(100) | At 10 minute | 0(0) | 2(100) | Present | 10(53) | 9(47) | Present | 6(22) | 21(78) | Present | 11(24) | 35(76) | |
| Moderate | 6(37.5) | 15(62.5) | After one hours | 6(27) | 15(73) | Absent | 5(12) | 37(88) | Absent | 9(26.5) | 25(73.5) | Absent | 4(27) | 11(73) | |
| Mild | 5(33) | 10(67) | After two hour | 5(38.5) | 10(61.5) | ||||||||||
| Absent | 4(27) | 11(73) | Not visualized | 4(27) | 11(73) | p(Adjust) | 0.975 | p(Adjust) | 0.105 | p(Adjust) | 0.998 | ||||
| p(Trend) | <0.001 | p(Trend) | 0.1461 | ||||||||||||
DUALN = degree uptake in axillary lymph nodes; VVAL = velocity visualization of axillary lymph nodes; classified according to Table 1.11 The presence or absence of radiopharmaceutical absorption by the liver (RAL), collateral circulation (CC) and dermal backflow (DBFL) were also analyzed
All analyses were adjusted for age and BMI
Lymphocintigraphy parameters DUALN, VVAL, DBFL, CC and RAL as related to the intervention group.
| AE | MLD | AE | MLD | AE | MLD | AE | MLD | AE | MLD | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 53 | n = 53 | n = 53 | n = 53 | n = 53 | n = 53 | n = 53 | n = 53 | n = 53 | n = 53 | ||||||
| DUALN | VVAL | DBFL | CC | RAL | |||||||||||
| Intense | 17(40.5) | 25(59.5) | At 10 minute | 21(47) | 24(53) | Present | 0(0) | 2(100) | Present | 14(58) | 10(42) | Present | 21(45) | 26(55) | |
| Moderate | 16(55) | 13(45) | After one hours | 10(47.5) | 21(52.5) | Absent | 47(48.5) | 50(51.5) | Absent | 31(42.5) | 42(57.5) | Absent | 32(55) | 26(45) | |
| Mild | 12(50) | 12(50) | After two hour | 5(50) | 5(50) | P | 0.5202 | p | 0.2643 | P | 0.3827 | ||||
| Absent | 8(80) | 29(20) | Not visualized | 8(80) | 2(20) | p(Adjust) | 0.224 | p(Adjust) | 0.148 | p(Adjust) | 0.360 | ||||
| p(Adjust) | 0.108 | p(Adjust) | 0.19 | ||||||||||||
| Intense | 9(41) | 13(59) | At 10 minute | 10(42) | 14(58) | Present | 1(25) | 3(75) | Present | 9(39) | 14(61) | Present | 37(51) | 35(49) | |
| Moderate | 11(44) | 14(56) | After one hours | 19(49) | 20(51) | Absent | 44(47) | 49(53) | Absent | 40(52) | 37(48) | Absent | 16(48.5) | 17(51.5) | |
| Mild | 16(47) | 18(53) | After two hour | 7(39) | 11(61) | p | 0.7157 | p | <0.001 | P | 0.9473 | ||||
| Absent | 8(53) | 7(47) | Not visualized | 8(53) | 7(47) | p(Adjust) | 0.491 | p(Adjust) | 0.374 | p(Adjust) | 0.412 | ||||
| p(Adjust) | 0.631 | p(Adjust) | 0.948 | ||||||||||||
| Intense | 7(44) | 9(56) | At 10 minute | 7(64) | 4(36) | Present | 10(53) | 9(47) | Present | 17(61) | 11(39) | Present | 24(51) | 23(49) | |
| Moderate | 10(62.5) | 6(37.5) | After one hours | 9(39) | 14(61) | Absent | 23(53.5) | 20(46.5) | Absent | 16(47) | 18(53) | Absent | 9(60) | 6(40) | |
| Mild | 7(47) | 8(53) | After two hour | 8(61.5) | 5(38.5) | p | 1 | p | 0.4141 | p | 0.759 | ||||
| Absent | 9(60) | 6(40) | Not visualized | 9(60) | 6(40) | p(Adjust) | 0.975 | p(Adjust) | 0.105 | p(Adjust) | 0.998 | ||||
| p(Adjust) | 0.85 | p(Adjust) | 0.81 |
DUALN = degree uptake in axillary lymph nodes; VVAL = velocity visualization of axillary lymph nodes; classified according to Table 1.11 The presence or absence of radiopharmaceutical absorption by the liver (RAL), collateral circulation (CC) and dermal backflow (DBFL) were also analyzed
All analyses were adjusted for age and BMI
Fig 3Recursive partitioning showing the factors associated with the presence of lymphedema after 30 months of follow-up.
Clinical features, postoperative complications and adjuvant treatment as related to the development of lymphedema after 30 months of follow-up.
| Lymphedema | p-value | ||||
|---|---|---|---|---|---|
| Yes | No | ||||
| N | % | n | % | ||
| 0.3980 | |||||
| AE | 11 | 30.6 | 25 | 69.4 | |
| MLD | 9 | 28.1 | 23 | 71.9 | |
| 20 | 55.1±17.5 | 48 | 59.2±13.0 | 0.4001 | |
| 20 | 28.07±5.96 | 48 | 28.37±5.96 | 0.7066 | |
| 0.4827 | |||||
| Yes | 6 | 33.3 | 19 | 40.4 | |
| No | 12 | 66.7 | 28 | 59.6 | |
| 0.9126 | |||||
| Yes | 3 | 16.7 | 6 | 12.8 | |
| No | 15 | 83.3 | 41 | 87.2 | |
| 0.2047 | |||||
| Yes | 6 | 33.3 | 13 | 27.7 | |
| No | 12 | 66.7 | 34 | 72.3 | |
| 0.5944 | |||||
| Yes | 15 | 75.0 | 25 | 52.1 | |
| No | 5 | 25.0 | 23 | 47.9 | |
| 0.9419 | |||||
| Yes | 16 | 80.0 | 25 | 54.3 | |
| No | 4 | 20.0 | 21 | 45.7 | |
| 0.9440 | |||||
| Yes | 14 | 82.4 | 35 | 76.1 | |
| No | 3 | 17.6 | 11 | 23.9 | |
Chi-Square test;
(*) Fisher’s Exact test;
SCF = supraclavicular fossa; SD = standard deviation